Monte Rosa Therapeutics, Inc. (GLUE) Stock Forecast
Data as of Oct 31, 2026Healthcare · Current price $10.69 (-1.66%)
Price Target Range
Consensus Price Target Over Time
Analyst Rating Distribution
Last 3 Months
6-Month Trend
Latest Analyst Forecasts
Price targets issued by Wall Street analysts. Upside calculated against today's price.
| Date | Analyst | Firm | Price Target | Upside |
|---|---|---|---|---|
| Dec 17, 2025 | Kelly Shi | Jefferies | $22.00 | +105.8% |
Top Analysts Covering GLUE
GLUE vs Sector & Market
| Metric | GLUE | Healthcare Avg | Large Cap Avg |
|---|---|---|---|
| Analyst Rating | 2.00 | 2.25 | 2.41 |
| Analyst Count | 9 | 8 | 19 |
| Target Upside | +132.3% | +153002.0% | +21.5% |
| P/E Ratio | -32.26 | 3.50 | 38.49 |
Revenue Estimates
| Period | Low | Avg | High | # |
|---|---|---|---|---|
| 2026-12-31 | $3M | $13M | $28M | 2 |
| 2027-03-31 | $1M | $5M | $11M | 2 |
| 2027-06-30 | $1M | $5M | $11M | 2 |
| 2027-09-30 | $1M | $5M | $11M | 2 |
| 2027-12-31 | $1M | $5M | $11M | 2 |
| 2028-12-31 | $7M | $21M | $46M | 5 |
| 2029-12-31 | $34M | $105M | $234M | 2 |
| 2030-12-31 | $54M | $168M | $374M | 2 |
EPS Estimates
| Period | Low | Avg | High | # |
|---|---|---|---|---|
| 2026-12-31 | $-1.02 | $-0.42 | $-0.01 | 2 |
| 2027-03-31 | $-1.31 | $-0.54 | $-0.01 | 2 |
| 2027-06-30 | $-1.40 | $-0.57 | $-0.01 | 1 |
| 2027-09-30 | $-1.39 | $-0.56 | $-0.01 | 1 |
| 2027-12-31 | $-1.45 | $-0.59 | $-0.01 | 2 |
| 2028-12-31 | $-2.90 | $-2.08 | $-0.57 | 5 |
| 2029-12-31 | $-4.91 | $-1.89 | $-0.22 | 1 |
| 2030-12-31 | $-3.60 | $-1.39 | $-0.16 | 1 |
Frequently Asked Questions
What is the analyst consensus for GLUE?
The consensus among 9 analysts covering Monte Rosa Therapeutics, Inc. (GLUE) is Buy with an average price target of $24.83.
What is the highest price target for GLUE?
The highest price target for GLUE is $22.00, set by Kelly Shi at Jefferies on 2025-12-17.
What is the lowest price target for GLUE?
The lowest price target for GLUE is $22.00, set by Kelly Shi at Jefferies on 2025-12-17.
How many analysts cover GLUE?
9 analysts have issued ratings for Monte Rosa Therapeutics, Inc. in the past 12 months.
Is GLUE a buy or sell right now?
Based on 9 analyst ratings, GLUE has a consensus rating of Buy (2.00/5) with a +132.3% upside to the consensus target of $24.83.
What are the earnings estimates for GLUE?
Analysts estimate GLUE will report EPS of $-0.42 for the period ending 2026-12-31, with revenue estimated at $13M.
Related Stock Forecasts
Data updated daily. Analyst price targets sourced from public filings and broker reports. Not investment advice.